{"id":"https://openalex.org/A5110181567","orcid":null,"observed_orcids":[],"display_name":"M L Dahl-Puustinen","raw_author_names":["M L Dahl-Puustinen","M. -L. Dahl-Puustinen","M.-L. Dahl-Puustinen","M.L Dahl-Puustinen","ML Dahl\u2010Puustinen"],"full_name":"M. -L. Dahl-Puustinen","works_count":6,"cited_by_count":120,"summary_stats":{"2yr_mean_citedness":0.0,"h_index":5,"i10_index":5},"ids":{"openalex":"https://openalex.org/A5110181567","orcid":null,"observed_orcids":[]},"affiliations":[{"institution":{"id":"https://openalex.org/I28166907","ror":"https://ror.org/056d84691","display_name":"Karolinska Institutet","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},"years":[1989]}],"last_known_institutions":null,"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","count":5,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10261","display_name":"Genetic Associations and Epidemiology","count":2,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","count":2,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12187","display_name":"Glutathione Transferases and Polymorphisms","count":2,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","count":1,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T12187","display_name":"Glutathione Transferases and Polymorphisms","value":3.66e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","value":1.16e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","value":8.1e-06,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","value":7.5e-06,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","value":4.6e-06,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.7253137826919556},{"id":"98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","score":0.5860629677772522},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.44417721033096313},{"id":"55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","score":0.31876569986343384},{"id":"181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","score":0.21918177604675293}],"counts_by_year":[{"year":1989,"works_count":4,"oa_works_count":0,"cited_by_count":0},{"year":1990,"works_count":2,"oa_works_count":2,"cited_by_count":0},{"year":2012,"works_count":0,"oa_works_count":0,"cited_by_count":3},{"year":2014,"works_count":0,"oa_works_count":0,"cited_by_count":2},{"year":2015,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2017,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2024,"works_count":0,"oa_works_count":0,"cited_by_count":2},{"year":2026,"works_count":0,"oa_works_count":0,"cited_by_count":1}],"display_name_alternatives":["M L Dahl-Puustinen","M. -L. Dahl-Puustinen","M.-L. Dahl-Puustinen","M.L Dahl-Puustinen","ML Dahl\u2010Puustinen"],"block_key":"m dahl-puustinen","works_api_url":"https://api.openalex.org/works?filter=author.id:A5110181567","updated_date":"2026-11-04T11:47:51","created_date":"2016-06-24T00:00:00"}